MINERALYS THERAPEUTICS INC (MLYS) Stock Price, Quote, News and Overview
NASDAQ:MLYS - Nasdaq - US6031701013 - Common Stock - Currency: USD
MLYS Quote, Performance and Key Statistics
10.52
-0.02 (-0.19%)
The current stock price of MLYS is 10.52 USD. In the past month the price increased by 4.68%. In the past year, price decreased by -25.39%.
MLYS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.17 | 378.30B | ||
| AMGN | AMGEN INC | 16.39 | 174.51B | ||
| GILD | GILEAD SCIENCES INC | 25.47 | 146.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1683.76 | 125.39B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.5 | 77.34B | ||
| ARGX | ARGENX SE - ADR | 231.21 | 36.10B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.66B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.47B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
| BIIB | BIOGEN INC | 9.13 | 22.01B | ||
| NTRA | NATERA INC | N/A | 19.02B | ||
| GMAB | GENMAB A/S -SP ADR | 24.89 | 15.34B |
Related stock screener links
About MLYS
Company Profile
Mineralys Therapeutics, Inc. s a clinical-stage biopharmaceutical company engaged in developing medicines to target disease, driven by abnormally elevated aldosterone. The company is headquartered in Radnor, Pennsylvania and currently employs 28 full-time employees. The company went IPO on 2023-02-10. The firm is focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone. The Company’s product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is initially developing for the treatment of patients with uncontrolled hypertension (uHTN). Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. The firm completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uHTN. In addition to hypertension, the Company intends to develop lorundrostat for the treatment of chronic kidney disease (CKD).
Company Info
MINERALYS THERAPEUTICS INC
150 N. Radnor Chester Road, Suite F200
Radnor PENNSYLVANIA US
Employees: 28
Company Website: https://mineralystx.com/
Investor Relations: https://ir.mineralystx.com/
Phone: 18883786240
MINERALYS THERAPEUTICS INC / MLYS FAQ
What is the stock price of MINERALYS THERAPEUTICS INC today?
The current stock price of MLYS is 10.52 USD. The price decreased by -0.19% in the last trading session.
What is the ticker symbol for MINERALYS THERAPEUTICS INC stock?
The exchange symbol of MINERALYS THERAPEUTICS INC is MLYS and it is listed on the Nasdaq exchange.
On which exchange is MLYS stock listed?
MLYS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MINERALYS THERAPEUTICS INC stock?
14 analysts have analysed MLYS and the average price target is 32.64 USD. This implies a price increase of 210.27% is expected in the next year compared to the current price of 10.52. Check the MINERALYS THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MINERALYS THERAPEUTICS INC worth?
MINERALYS THERAPEUTICS INC (MLYS) has a market capitalization of 524.32M USD. This makes MLYS a Small Cap stock.
How many employees does MINERALYS THERAPEUTICS INC have?
MINERALYS THERAPEUTICS INC (MLYS) currently has 28 employees.
What are the support and resistance levels for MINERALYS THERAPEUTICS INC (MLYS) stock?
MINERALYS THERAPEUTICS INC (MLYS) has a support level at 9.13 and a resistance level at 10.53. Check the full technical report for a detailed analysis of MLYS support and resistance levels.
Should I buy MINERALYS THERAPEUTICS INC (MLYS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MLYS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MLYS, evaluating the profitability, health, valuation and growth aspects
- MINERALYS THERAPEUTICS INC (MLYS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MINERALYS THERAPEUTICS INC (MLYS) Sales and EPS estimates to see what analysts future expectations are.
- MINERALYS THERAPEUTICS INC (MLYS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MINERALYS THERAPEUTICS INC (MLYS) Insider and Institutional Ownership to learn about the owners and their transactions.
- MINERALYS THERAPEUTICS INC (MLYS) Stock Chart to make your own analysis
- MINERALYS THERAPEUTICS INC (MLYS) Latest news and press-releases to stay up to date.
Does MINERALYS THERAPEUTICS INC (MLYS) stock pay dividends?
MLYS does not pay a dividend.
When does MINERALYS THERAPEUTICS INC (MLYS) report earnings?
MINERALYS THERAPEUTICS INC (MLYS) will report earnings on 2025-05-07.
What is the Price/Earnings (PE) ratio of MINERALYS THERAPEUTICS INC (MLYS)?
MINERALYS THERAPEUTICS INC (MLYS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.64).
What is the Short Interest ratio of MINERALYS THERAPEUTICS INC (MLYS) stock?
The outstanding short interest for MINERALYS THERAPEUTICS INC (MLYS) is 4.15% of its float. Check the ownership tab for more information on the MLYS short interest.
MLYS Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to MLYS. When comparing the yearly performance of all stocks, MLYS is a bad performer in the overall market: 83.34% of all stocks are doing better.
MLYS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MLYS. While MLYS has a great health rating, there are worries on its profitability.
MLYS Financial Highlights
Over the last trailing twelve months MLYS reported a non-GAAP Earnings per Share(EPS) of -3.64. The EPS decreased by -82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -86.36% | ||
| ROE | -92.97% | ||
| Debt/Equity | 0 |
MLYS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to MLYS. The Buy consensus is the average rating of analysts ratings from 14 analysts.